Share on StockTwits

DaVita HealthCare Partners (NYSE:DVA) VP Leanne M. Zumwalt sold 3,214 shares of DaVita HealthCare Partners stock on the open market in a transaction that occurred on Wednesday, August 27th. The shares were sold at an average price of $74.57, for a total transaction of $239,667.98. Following the transaction, the vice president now directly owns 7,194 shares in the company, valued at approximately $536,457. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Shares of DaVita HealthCare Partners (NYSE:DVA) traded up 0.35% during mid-day trading on Friday, hitting $74.68. The stock had a trading volume of 544,888 shares. DaVita HealthCare Partners has a 1-year low of $52.75 and a 1-year high of $74.84. The stock’s 50-day moving average is $72.61 and its 200-day moving average is $70.05. The company has a market cap of $16.041 billion and a P/E ratio of 23.56.

DaVita HealthCare Partners (NYSE:DVA) last issued its quarterly earnings results on Thursday, July 31st. The company reported $0.95 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.89 by $0.06. The company had revenue of $3.17 billion for the quarter, compared to the consensus estimate of $3.10 billion. During the same quarter last year, the company posted $1.84 earnings per share. DaVita HealthCare Partners’s revenue was up 10.5% compared to the same quarter last year. Analysts expect that DaVita HealthCare Partners will post $3.62 EPS for the current fiscal year.

A number of analysts have recently weighed in on DVA shares. Analysts at Deutsche Bank downgraded shares of DaVita HealthCare Partners from a “buy” rating to a “hold” rating in a research note on Friday, August 15th. They now have a $77.00 price target on the stock. They noted that the move was a valuation call. Separately, analysts at Zacks reiterated a “neutral” rating on shares of DaVita HealthCare Partners in a research note on Friday, August 1st. They now have a $74.00 price target on the stock. Finally, analysts at Raymond James downgraded shares of DaVita HealthCare Partners from an “outperform” rating to a “market perform” rating in a research note on Monday, July 21st. They now have a $75.00 price target on the stock. Five research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $75.33.

DaVita HealthCare Partners Inc, formerly DaVita Inc, is a provider of dialysis services in the United States for patients suffering from chronic kidney failure, also known as end stage renal disease (NYSE:DVA).

Receive News & Ratings for DaVita HealthCare Partners Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita HealthCare Partners Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.